- Research Services
- Capabilities
- About Us
- Resources
- Contact Us
Xenograft mouse models utilize transplantation of human tumor cells (cell line-derived xenograft – CDX) or direct human cancer tissue (patient-derived xenograft – PDX) into humanized or immunocompromised mice to emulate a variety of human cancers. Both cell line-derived and patient-derived models can be performed with heterotopic or orthotopic implantation methods and are effective tools for assessing the efficacy of therapeutic candidates in the oncology space. Xenograft studies can provide highly translational data on novel anti-cancer compounds given the original, human properties and characteristics of the tumors. BioModels has significant experience in this area and can help to design and execute xenograft model programs with customizable, translational, experimental endpoints including model characterization, ex vivo cellular assays, biomarker evaluation, hematology analyses, and more.
Human squamous cell carcinoma tumor cells expressing a bioluminescent reporter (SSC-25-Luc2) are seeded into the tongue of immunocompromised mice. Group 2 animals are subject to fractionated radiation therapy, and tumor growth is monitored via IVIS imaging to detect luminescence.
Immunocompromised mice are seeded with human squamous cell carcinoma tumor cells in the tongue. Group 2 animals are subject to fractionated radiotherapy, and tumor responses are measured with whole body imaging to detect luminescence. Whole body mean radiant flux (IVIS) values are shown with AUC analysis.
Patient-derived pancreatic cancer tumors expressing a bioluminescent reporter (PANx-005-Luc) are orthotopically seeded into immunocompromised mice. Groups 2 and 3 are subject to chemotherapy and experimental treatments. Tumor growth is monitored via imaging with an IVIS to detect luminescence.
Patient-derived pancreatic cancer tumors expressing a bioluminescent reporter (PANx-005-Luc) are orthotopically seeded into immunocompromised mice. Groups 2 and 3 are subject to chemotherapy and experimental treatments, and tumor responses are measured with whole body imaging to detect luminescence. Whole body mean radiant flux values are shown with AUC analysis.
